Get started

Swingtrading

IOLCP Showing Change in Structure can go towards 52 Week HighNSE:IOLCP ...................................................................................................................... ...................................................................................................................... The Company’s turnover increased to ₹ 2,133 crore in FY24 from ₹ 983 crore in FY18 at a CAGR of 13.77% ...................................................................................................................... ...................................................................................................................... The share of regulated market sale has increased to ₹ 300 crore in FY24 from ₹100 crore in FY18 ...................................................................................................................... ...................................................................................................................... Increased contribution of non-Ibuprofen drugs from ₹35 crore in FY18 to ₹431 crore in FY24, showing a steady upward trend over the years ...................................................................................................................... ...................................................................................................................... Added more than 10 products since 2017 in APIs and chemical segments. The Company has recently commenced a new plant of Acetic Anhydride ...................................................................................................................... ...................................................................................................................... • The Indian API market is expected to grow at a CAGR of 13.7% over the four years. • India hosts 500 API manufacturers, contributing approximately 8% to the global API Industry. • As the largest supplier of generic medicines, India manufactures around 60,000 different generic brands across 60 therapeutic categories. • In FY24 India saw a 4.12% increase in the total imports of bulk drugs and intermediates, amounting to ₹ 37,721.88 crore, compared to ₹ 36,229.15 crore in FY23. • Indian medicines are preferred worldwide due to their combination of low price and high quality, earning India the title of "pharmacy of the world." ...................................................................................................................... ...................................................................................................................... Positive factors • Strongly improving operating performance, resulting in growth of more than 15% in total operating income and sustained EBIDTA margin of more than 20%, on a sustained. • Diversifying product portfolio and reducing dependency on its main product Ibuprofen and ethyl acetate to below 65% in the overall revenue. • Improving total debt to gross cash accruals (TD/GCA) and TD to profit before interest, lease rentals, depreciation, and taxation (TD/PBILDT) to below unity. ...................................................................................................................... ...................................................................................................................... Established market position and diversified product offering The company was incorporated, 1986 with the commencement of business in chemical segment. In 2000, the company started production of Ibuprofen. IOLCPL is one of the largest manufacturers of Ibuprofen with significant global share and the company is backward integrated for manufacturing Ibuprofen. IOLCPL has a market presence across more than 50 countries with sales contribution from exports forming around 28% of total sales in FY24 (PY: 29%). The company’s overseas customers are spread across Switzerland, Bangladesh, Spain, Indonesia, Hungary, United Kingdom, Nepal, China, Turkey and Japan, among others. The company is one of the largest manufacturers of Ibuprofen (capacity of 12000 MTPA) and has the second largest manufacturing capacity (12000MTPA) for Iso Butyl Benzene (key raw material for Ibuprofen)
NSE:IOLCPLong
by iism-ExpertTrading
ASX 200 mimics Wall Street's 'risk-on' rally into Jackson HoleOverbought indicators are of little use when markets are obsessed with rate cuts ahead of a key fed speech. Jerome Powell will speak at the Jackson hole symposium and Friday, and expectations for a dovish show are high. And that's helped Wall Street indices extend gains and the allowed the ASX 200 to tag along for the ride. But if this turns out to be a classic 'buy the rumour, sell the fact' tale, traders may need to factor in some of the overbought clues on the daily chart.
ASX24:AP1!Short
by CityIndex
USD/JPY: Seeking dips above 144USD bears are getting quite excited at the prospects of a dovish speech from Jerome Powell on Friday. Perhaps a bit too excited. Market pricing has been quite dovish for some time now, so he will really have to crank up the dovish music on Friday to justify the latest surge of USD selling. USD/JPY fell over -12.5% from the July high to August low, yet formed a higher low above the Dec/Jan lows. We suspect a deeper retracement against that initial drop could be due. However, momentum is trying to turn lower on the 4-hour chart. Out bias is bullish while prices remain above 144, and will seek dips towards that level. A false break of Monday's low could work nicely (assuming prices pull back that far), in anticipation of a move back towards 150.
Long
by CityIndex
1
RUPA indicating is No More an Ordinary Underwear BrandNSE:RUPA Commenting on the financial performance Mr. Vikash Agarwal - Whole Time Director, said, “We are pleased to report a stable performance in Q1 FY25, though the industry continues to witness resistance to any price increase. We demonstrated steady improvements across key financial metrics. This quarter, we witnessed 8% rise in revenue, primarily driven by strong sales in our core product line. Our volume growth for the quarter reached 9%, supported by strong sales in the economy and athleisure segments. Our EBITDA saw a year-on-year increase of 59%, totaling Rs. 18.0 crores for the quarter, showcasing our commitment to cost management and operational efficiency. Operating margins also improved by 280 basis points compared to the same period last year. Furthermore, our net profit experienced substantial growth of 149%, reaching Rs. 10.5 crores for the quarter. This underscores the effectiveness of our financial strategies and the resilience of our business model. Net profit margins improved by 280 basis points during the quarter. Notably, our exports have shown progress, with a healthy 32% year-on-year growth, reaching Rs. 8 crores. This reflects our steady penetration into international markets. Revenue contribution from Modern Trade remains robust at 8% in Q1 FY25. The pilot project “Pragati’, which was launched last quarter, has received encouraging feedback from our distributors. We expect healthy expansion of the project going forward. Our cash flow from operations remains strong, generating Rs. 44 crores in Q1 FY25. We have made significant progress in reducing our debt, achieving a net debt-free status as at end of Q1 FY25. Our branding and advertising strategies accounted for 9% of revenues in Q1 FY25. Looking ahead, we are confident in achieving new business milestones and delivering innovative products to our diverse customer segments. Our customer-first approach will help us strengthen our position as an industry leader and contribute to our sustainable business model
NSE:RUPALong
by iism-ExpertTrading
FIEMIND Turned ON its Marubozu Headlights At ALL TIME HIGH ZONE NSE:FIEMIND GOVT. APPROVED R&D CENTRE • FIEM’s state of the art R&D Centre offers its clients design and development capabilities in Automotive Lighting & Signalling Equipments and Rear View Mirrors which meet the specifications of the clients requirements. • Government of India, Ministry of Science and Technology, Department of Science and Industrial Research has accorded Recognition to Company’s in-house R&D Unit situated at Rai Industrial Estate, Sonepat. • The Company’s R&D Centre is established with modern infrastructure, state-of-the-art technology, equipped with latest software, qualified and experienced manpower. • FIEM’s in-house R&D Centre has various kinds of testing facilities such as Product Testing, Photometry Testing, Environmental Testing, Thermal Tests, Electronic Test, Vibration Test, Chemical Test, Mechanical Tests etc. • Photometry Laboratory of the Company is NABL Accredited. • Some examples of R&D conducted by company: • In-house design and development of Railway IPIS (Integrated Passenger Information Systems with LED Display) • In-house design and development for four wheeler LED Rear combination, LED direction indicator light etc. • Advantages of in-house R&D unit: • Diversified and large portfolio of lighting products developed. • New generation LED technology in automotive and home lighting segments developed. • Reduction in development time and cost savings to clients. Company is almost debt free. Company has delivered good profit growth of 24.4% CAGR over last 5 years Company has been maintaining a healthy dividend payout of 29.3%
NSE:FIEMINDLong
by iism-ExpertTrading
INDOAMIN Showing Volume Strength near ALL TIME HIGH Zone NSE:INDOAMIN Strengths: Established market position: IAL was promoted by Mr Vijay B Palkar in 1979, as Techno Chemical Industries, and converted to IAL in 1992. Over the years, the promoters have developed strong expertise in the chemical industry. The company now manufactures oleo, specialty and performance chemicals, used across various industries, such as pharmaceuticals, agrochemicals, fertilizers, petrochemicals, pesticides and perfumeries. Benefits from the longstanding presence of the promoters in the chemical industry and their established relationships with customers and suppliers will continue over medium term. Above average financial risk profile: The financial risk profile is above average with a robust net worth of around Rs. 213.86 crore as on March 31, 2023. This supports the financial flexibility of the group. Supported by a robust net worth the capital structure is moderate with total outside liabilities to adjusted networth (TOLANW) of 1.72 time as on March 31, 2023. This is expected to remain comfortable going forward. Capital structure is expected to improve over medium term on the back of healthy accruals, absence of large debt funded capex and scheduled repayments. Overall financial risk profile is expected to further improve over medium term.
NSE:INDOAMINLong
by iism-ExpertTrading
#polyplex ready for 25% upmove?Polyplex corporation on weekly time frame has closed above the strong resistance of WEMA100 & 200 this week. Above this week's high of 1311 it can try to touch 1516/1630/1680, below 1034 it will once again enter into bearish territory. I will try to enter at retest of DEMA21 around 1140/1137 where risk reward will be maximum. Tomorrow will be an interesting day for this stock, lets see how it performs. Since I am not SEBI registered, please enter in this stock at your risk and speak to your registered consultant before taking this trade
NSE:POLYPLEXLong
by ssudhirsharma11
SWING IDEA - VENUSREMNSE:VENUSREM seems to be freshly coming out of the Cup and Handle Pattern. Co-incidentally, its is also at a Support/Resistance Level of 404. It can also be noticed that there was a Convergence Divergence at the MACD Crossover a couple of years ago. After which, we see a another good MACD crossover happening at a crucial level, where the Cup & Handle Pattern also completes, exactly near the Support/Resistance zone. If all is well, this Setup can play well at least until the next Swing High Level.
NSE:VENUSREMLong
by thepranam
SWING IDEA - VIP INDUSTRIESVIP Industries , a leading manufacturer of luggage and travel accessories, is displaying technical indicators that suggest a promising swing trading opportunity. Reasons are listed below : 450-500 Strong Support Zone : The 450-500 level has been established as a strong support zone, providing a solid base for potential upward movement. Bullish Engulfing Candle on Weekly Timeframe : The formation of a bullish engulfing candle on the weekly chart indicates strong buying pressure and suggests potential for further upward movement. Daily Candle Engulfed 7 Daily Candles : The recent daily candle has engulfed the previous 7 daily candles, demonstrating significant buying interest and a potential shift in trend. Golden Fibonacci Zone : The stock is finding support at the golden Fibonacci retracement level (0.618), a key area where prices often bounce back, indicating potential for an upward move. Increased Volumes : A noticeable increase in trading volumes confirms the strength of the price move and indicates growing investor interest. Target - 575 // 660 // 715 Stoploss - weekly close below 445 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:VIPINDLong
by Visionary_Growth_Insights
$IBM Support Levels HoldingNYSE:IBM did not have a great earnings report for the 1st Quarter 2024, but 2nd quarter improved. The stock has one of the better charts in the Dow 30 components. It has held up better than most of the Dow components, except for those stocks that are in buyback mode. It has been tapering off its buybacks for 2 quarters. So the gains holding above the support lows are not from buybacks. There are accumulation patterns and pro trader activity in the mix. One to watch for swing trading potential.
NYSE:IBM
by MarthaStokesCMT-TechniTrader
Apollo Hospital-Swing Trade-Will this be the end of Downtrend? NSE:APOLLOHOSP 16.07.2024 Buy strictly above 6477 Target 6820 Stop Loss 6247 Risk Reward- 1:1.5 1. Inside bar breakout in day TF & Bullish engulf in weekly TF 2. Price has formed double bottom at key level & also rejected from 200 EMA 3. Later breakdown found by crossing lower low and found retracement. 4. Now price has crossed previous LL where we can consider strong resistance 5. 21 & 50 EMA Crossover found at retracement level 6. From the downtrend view price has just crossed 0.618 level. Need the rejection from further upmove 7. Volumes are good but still need more to accumulate for upmove. 8. Pharma & Healthcare sector is in good shape 9. Rejection also found in FVG
NSE:APOLLOHOSPLong
by Swinging_Inside_the_BAR